Spyre Therapeutics Reports Positive Phase 2 Data for SPY002 in Ulcerative Colitis, Meeting Primary Endpoint

summarizeSummary

Spyre Therapeutics reported positive 12-week induction data from its Phase 2 SKYLINE trial for SPY002 in ulcerative colitis, meeting the primary endpoint and demonstrating strong efficacy and a favorable safety profile.

check_boxKey Events

• SPY002 Achieves Primary Endpoint

  SPY002 met its primary endpoint in the Phase 2 SKYLINE trial for ulcerative colitis, demonstrating a statistically significant 10.7-point reduction in Robarts Histopathology Index (RHI) score (p<0.0001) at Week 12.

• Strong Secondary Efficacy Outcomes

  The trial reported robust rates of clinical remission (33%) and endoscopic improvement (42%), along with a meaningful change in modified Mayo Score (-3.7), which are noted as being among the highest reported in UC.

• Favorable Safety Profile

  SPY002 was well tolerated with a safety profile consistent with the TL1A class. Two serious adverse events were reported but deemed not drug-related.

• Pipeline Advancement and Future Readouts

  These results build upon impressive SPY001 data and reinforce the company's strategy for optimized monotherapy components. Spyre remains on track to report Part A data for SPY003 (anti-IL-23) in Q3 2026 and is enrolling Part B of the SKYLINE trial for combination arms.

auto_awesomeAnalysis

Spyre Therapeutics announced highly positive Phase 2 SKYLINE trial data for SPY002 in ulcerative colitis, achieving its primary endpoint with a statistically significant reduction in the RHI score. The results, described as 'among the highest reported in UC' and 'potential best-in-class,' significantly de-risk the program and bolster the company's pipeline, especially following previous positive data for SPY001. This strong clinical validation could accelerate SPY002's development and enhance its market potential.